A Phase 3 interventional study of SYD-101 0.01% and SYD-101 0.03% in Nearsightedness, Near Sightedness and Near-sightedness, sponsored by Sydnexis, Inc.. Completed at 47 sites in 3 countries. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Sydnexis, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.
Among the 54 studies testing atropine in Myopia, this one has the largest enrollment, is one of 5 that started in 2019, is one of 13 in phase 3, and was the 19th registered.
1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages 5–11
Ohio State University · Sites in United States
Ages 6–11 · Healthy volunteers
IDB VisionCare SDN BHD · Sites in Malaysia
Ages 5–10
Ocus Innovation Ireland Limited · Sites in Albania, Italy, Poland and 2 more countries
Ages 3–17
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
By country, each count listing its studies:
Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 3 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 16 · Phase 4 8
First in 2005; this study’s year is marked. 5 started in 2019.
This study's enrollment of 852 is above the median of 79 across 926 interventional studies indexed under Myopia.
Median enrollment 144 across the 54 interventional studies. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 54 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sydnexis, Inc. as lead sponsor.
Sydnexis, Inc. has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
8 of the studies testing atropine in Myopia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07329777Phase 3IDB VisionCare SDN BHDAtropine in the Treatment of Myopia Study in Malaysia | 2027-09 |
| NCT07164092Phase 3Mansoura UniversityEfficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center | 2027-09 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
| NCT05379855Eye & ENT Hospital of Fudan UniversityA-eyedrops on Ocular Alignment and Binocular Vision | 2027-02-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 54 studies testing atropine in Myopia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of developing other eye conditions such as glucoma, cataracts and retinal detachment, which may lead to blindness. Early treatment of myopia in children could help slow the condition and minimize the risk of complications later in life. This study investigates the use of SYD-101, an eye solution, in slowing-down the progression of myopia in children.
This will be a 3-arm, multicentered, randomized, double-masked, vehicle-controlled study conducted in 2 parts.
Part 1 is the primary treatment period of 3 years, during which participants will receive 1 of 3 masked medications.
Part 2 is the randomized withdrawal period of 1 year, during which participants originally receiving Vehicle will receive SYD-101, and participants originally receiving SYD-101 will receive either Vehicle or SYD-101.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria could apply.
1 drop in each eye at bedtime. Part 1: participants will be randomized to SYD-101 0.01% Part 2: participants will be re-randomized to SYD-101 0.01% or Vehicle
Drug: SYD-101 0.01%
1 drop in each eye at bedtime. Part 1: participants will be randomized to SYD-101 0.03% Part 2: participants will be re-randomized to SYD-101 0.03% or Vehicle
Drug: SYD-101 0.03%
1 drop in each eye at bedtime. Part 1: participants will be randomized to Vehicle Part 2: participants will be re-randomized to SYD-101 0.03%
Drug: Vehicle
Sterile topical ophthalmic solution
Also known as: atropine sulfate
Sterile topical ophthalmic solution
Also known as: atropine sulfate
Sterile topical ophthalmic solution without active ingredient
Also known as: Placebo
Myopic Progression <-0.75 D (Diopters)
Proportion of participants with confirmed myopic progression \<-0.75 D (diopters), based on SE (spherical equivalent) as measured by cycloplegic autorefraction
Time frame: Month 36
Mean Annual Myopic Progression
Mean annual progression rate of myopia measured in diopters: Spherical Equivalent (SE) as measured by cycloplegic autorefraction.
Time frame: Month 36
Proportion of Participants With Annual Myopia Progression Rate >=-0.50 D/Year
Proportion of participants with annual progression rate of myopia no worse than -0.50 D/year
Time frame: Through Month 36
Proportion of Participants With Annual Myopia Progression Rate >=-0.25 D/Year
Proportion of participants with annual progression rate of myopia no worse than -0.25D/year
Time frame: Through Month 36
Proportion of Participants With Increase of Myopia More Than -0.50 D
Proportion of participants with increase of myopia more than -0.50D
Time frame: Month 36
Time to Progression of Myopia <-0.75 D (Diopters)
Time (days) to confirmed myopic progression of worse than -0.75D. Time to Progression (days) 95% CI is calculated for the median.
Time frame: Up to 36 months (from date of randomization until date myopia progresses < -0.75 D)
Mean Change From Baseline in Axial Length (Subset Only)
Mean change from baseline in axial length at sites with requisite equipment
Time frame: Baseline to Month 36
| Milestone | Part 1: SYD-101 0.01% | Part 1: SYD-101 0.03% | Part 1: Vehicle | Part 2: SYD-101 0.01% | Part 2: SYD-101 0.03% | Part 2: 0.01% to Vehicle | Part 2: 0.03% to Vehicle | Part 2: Vehicle to SYD-101 0.03% |
|---|---|---|---|---|---|---|---|---|
| Started | 284 | 285 | 283 | 0 | 0 | 0 | 0 | 0 |
| Received study medication | 282 | 283 | 282 | 0 | 0 | 0 | 0 | 0 |
| Initiated escape medication | 1 | 5 | 12 | 0 | 0 | 0 | 0 | 0 |
| Completed | 211 | 223 | 224 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 73 | 62 | 59 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 38 | 33 | 33 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 31 | 22 | 21 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision, non-compliance, moved | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not receive study medication | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: SYD-101 0.01% | Part 1: SYD-101 0.03% | Part 1: Vehicle | Part 2: SYD-101 0.01% | Part 2: SYD-101 0.03% | Part 2: 0.01% to Vehicle | Part 2: 0.03% to Vehicle | Part 2: Vehicle to SYD-101 0.03% |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 102 | 105 | 103 | 105 | 205 |
| Continued escape medication | 1 | 5 | 12 | 0 | 0 | 0 | 0 | 0 |
| Initiated escape medication | 0 | 0 | 0 | 8 | 8 | 7 | 10 | 9 |
| Completed | 0 | 0 | 0 | 99 | 102 | 98 | 101 | 186 |
| Not completed | 0 | 0 | 0 | 3 | 3 | 5 | 4 | 19 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 1 | 2 | 2 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 2 | 3 | 1 | 7 |
| Withdrew: Physician decision, protocol deviation, non-compliance, other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
Proportion of participants with confirmed myopic progression \<-0.75 D (diopters), based on SE (spherical equivalent) as measured by cycloplegic autorefraction
| Participants | SYD-101 0.01% | SYD-101 0.03% | Vehicle |
|---|---|---|---|
| Myopic Progression <-0.75 D (Diopters) | 111 | 122 | 139 |
Mean annual progression rate of myopia measured in diopters: Spherical Equivalent (SE) as measured by cycloplegic autorefraction.
| Diopters/year | SYD-101 0.01% | SYD-101 0.03% | Vehicle |
|---|---|---|---|
| Mean Annual Myopic Progression | -0.30 (-0.34 to -0.27) | -0.32 (-0.35 to -0.28) | -0.38 (-0.42 to -0.34) |
Proportion of participants with annual progression rate of myopia no worse than -0.50 D/year
| Participants | SYD-101 0.01% | SYD-101 0.03% | Vehicle |
|---|---|---|---|
| Proportion of Participants With Annual Myopia Progression Rate >=-0.50 D/Year | 240 | 238 | 227 |
Proportion of participants with annual progression rate of myopia no worse than -0.25D/year
| Participants | SYD-101 0.01% | SYD-101 0.03% | Vehicle |
|---|---|---|---|
| Proportion of Participants With Annual Myopia Progression Rate >=-0.25 D/Year | 163 | 150 | 131 |
Proportion of participants with increase of myopia more than -0.50D
| Participants | SYD-101 0.01% | SYD-101 0.03% | Vehicle |
|---|---|---|---|
| Proportion of Participants With Increase of Myopia More Than -0.50 D | 160 | 171 | 189 |
Time (days) to confirmed myopic progression of worse than -0.75D. Time to Progression (days) 95% CI is calculated for the median.
| Days | SYD-101 0.01% | SYD-101 0.03% | Vehicle |
|---|---|---|---|
| Time to Progression of Myopia <-0.75 D (Diopters) | NA (1101.00 to NA) | 1112.0 (1099.00 to NA) | 1104.0 (916.00 to NA) |
Mean change from baseline in axial length at sites with requisite equipment
| millimeters | SYD-101 0.01% | SYD-101 0.03% | Vehicle |
|---|---|---|---|
| Mean Change From Baseline in Axial Length (Subset Only) | 0.46 (0.39 to 0.54) | 0.44 (0.36 to 0.51) | 0.48 (0.40 to 0.55) |
Collected over 48 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: SYD-101 0.01% | 0/282 (0%) | 4/282 (1.4%) | 183/282 (64.9%) |
| Part 1: SYD-101 0.03% | 0/283 (0%) | 10/283 (3.5%) | 205/283 (72.4%) |
| Part 1: Vehicle | 0/282 (0%) | 8/282 (2.8%) | 194/282 (68.8%) |
| Escape Med: 0.03% | 0/50 (0%) | 0/50 (0%) | 17/50 (34%) |
| Part 2: SYD-101 0.01% | 0/102 (0%) | 0/102 (0%) | 14/102 (13.7%) |
| Part 2: SYD-101 0.03% | 0/105 (0%) | 0/105 (0%) | 17/105 (16.2%) |
| Part 2: 0.01% to Vehicle | 0/103 (0%) | 0/103 (0%) | 9/103 (8.7%) |
| Part 2: 0.03% to Vehicle | 0/105 (0%) | 0/105 (0%) | 14/105 (13.3%) |
| Part 2: Vehicle to 0.03% | 0/205 (0%) | 1/205 (0.5%) | 60/205 (29.3%) |
| Event | Part 1: SYD-101 0.01% | Part 1: SYD-101 0.03% | Part 1: Vehicle | Escape Med: 0.03% | Part 2: SYD-101 0.01% | Part 2: SYD-101 0.03% | Part 2: 0.01% to Vehicle | Part 2: 0.03% to Vehicle | Part 2: Vehicle to 0.03% |
|---|---|---|---|---|---|---|---|---|---|
| Suicidal ideationPsychiatric disorders | 0/282 | 0/283 | 2/282 | 0/50 | 0/102 | 0/105 | 0/103 | 0/105 | 0/205 |
| Ulcerative colitisGastrointestinal disorders | 1/282 | 0/283 | 0/282 | 0/50 | 0/102 | 0/105 | 0/103 | 0/105 | 1/205 |
| Pneumonia aspirationInfections and infestations | 0/282 | 0/283 | 0/282 | 0/50 | 0/102 | 0/105 | 0/103 | 0/105 | 1/205 |
| Craniocerebral injuryInjury, poisoning and procedural complications | 0/282 | 0/283 | 0/282 | 0/50 | 0/102 | 0/105 | 0/103 | 0/105 | 1/205 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/282 | 0/283 | 0/282 | 0/50 | 0/102 | 0/105 | 0/103 | 0/105 | 1/205 |
| Pulmonary contusionInjury, poisoning and procedural complications | 0/282 | 0/283 | 0/282 | 0/50 | 0/102 | 0/105 | 0/103 | 0/105 | 1/205 |
| Non fatal intentional drug overdoseInjury, poisoning and procedural complications | 1/282 | 0/283 | 1/282 | 0/50 | 0/102 | 0/105 | 0/103 | 0/105 | 0/205 |
| Commotio cerebriInjury, poisoning and procedural complications | 1/282 | 0/283 | 0/282 | 0/50 | 0/102 | 0/105 | 0/103 | 0/105 | 0/205 |
| PapilledemaEye disorders | 1/282 | 0/283 | 0/282 | 0/50 | 0/102 | 0/105 | 0/103 | 0/105 | 0/205 |
| Transient vision lossEye disorders | 0/282 | 0/283 | 1/282 | 0/50 | 0/102 | 0/105 | 0/103 | 0/105 | 0/205 |
| Event | Part 1: SYD-101 0.01% | Part 1: SYD-101 0.03% | Part 1: Vehicle | Escape Med: 0.03% | Part 2: SYD-101 0.01% | Part 2: SYD-101 0.03% | Part 2: 0.01% to Vehicle | Part 2: 0.03% to Vehicle | Part 2: Vehicle to 0.03% |
|---|---|---|---|---|---|---|---|---|---|
| PhotophobiaEye disorders | 72/282 | 89/283 | 53/282 | 5/50 | 3/102 | 5/105 | 1/103 | 0/105 | 19/205 |
| Vision blurredEye disorders | 30/282 | 54/283 | 26/282 | 2/50 | 0/102 | 1/105 | 0/103 | 2/105 | 11/205 |
| HeadacheNervous system disorders | 35/282 | 46/283 | 51/282 | 3/50 | 3/102 | 4/105 | 2/103 | 4/105 | 6/205 |
| COVID 19Infections and infestations | 30/282 | 33/283 | 46/282 | 3/50 | 0/102 | 2/105 | 0/103 | 2/105 | 4/205 |
| Instillation site irritationGeneral disorders | 24/282 | 27/283 | 29/282 | 1/50 | 0/102 | 1/105 | 0/103 | 0/105 | 1/205 |
| MydriasisEye disorders | 5/282 | 21/283 | 4/282 | 2/50 | 0/102 | 0/105 | 0/103 | 0/105 | 8/205 |
| Foreign body sensationEye disorders | 20/282 | 17/283 | 19/282 | 0/50 | 0/102 | 1/105 | 0/103 | 1/105 | 0/205 |
| Eye painEye disorders | 9/282 | 11/283 | 14/282 | 0/50 | 0/102 | 0/105 | 1/103 | 1/105 | 0/205 |
| NasopharyngitisInfections and infestations | 13/282 | 14/283 | 10/282 | 0/50 | 2/102 | 0/105 | 1/103 | 2/105 | 2/205 |
| Eye irritationEye disorders | 9/282 | 6/283 | 12/282 | 0/50 | 3/102 | 2/105 | 0/103 | 0/105 | 2/205 |
| Age, Continuous(years) | SYD-101 0.01% | SYD-101 0.03% | Vehicle | Total |
|---|---|---|---|---|
| Mean | 10.4 ± 2.44 | 10.2 ± 2.46 | 10.4 ± 2.42 | 10.3 ± 2.44 |
| Sex: Female, Male(Participants) | SYD-101 0.01% | SYD-101 0.03% | Vehicle | Total |
|---|---|---|---|---|
| Female | 167 | 156 | 149 | 472 |
| Male | 115 | 127 | 133 | 375 |
| Ethnicity (NIH/OMB)(Participants) | SYD-101 0.01% | SYD-101 0.03% | Vehicle | Total |
|---|---|---|---|---|
| Hispanic or Latino | 74 | 71 | 81 | 226 |
| Not Hispanic or Latino | 208 | 212 | 201 | 621 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SYD-101 0.01% | SYD-101 0.03% | Vehicle | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 3 | 4 | 9 |
| Asian | 46 | 55 | 47 | 148 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 2 | 3 |
| Black or African American | 35 | 22 | 21 | 78 |
| White | 190 | 192 | 198 | 580 |
| More than one race | 4 | 8 | 4 | 16 |
| Unknown or Not Reported | 4 | 3 | 6 | 13 |
| Region of Enrollment(participants) | SYD-101 0.01% | SYD-101 0.03% | Vehicle | Total |
|---|---|---|---|---|
| Austria | 6 | 10 | 10 | 26 |
| United States | 263 | 256 | 258 | 777 |
| Slovakia | 13 | 17 | 14 | 44 |
| Baseline Spherical Equivalent(Diopters) | SYD-101 0.01% | SYD-101 0.03% | Vehicle | Total |
|---|---|---|---|---|
| Mean | -2.73 ± 1.375 | -2.65 ± 1.286 | -2.70 ± 1.267 | -2.69 ± 1.309 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in May 2024, 60 months.
Results were first posted in Jul 2026, 2 years 2 months after primary completion. A results delay was requested in Feb 2025.
Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's 60 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atropine